A pharmacokinetic study of clazosentan in patients with aneurysmal subarachnoid haemorrhage

P. L.M. Van Giersbergen, P. Vajkoczy, B. Meyer, S. Weidauer, A. Raabe, C. Thome, F. Ringel, V. Breu, P. Schmiedek, Jasper Dingemanse

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

3 Scopus citations

Abstract

The objective of this study was to evaluate the pharmacokinetics of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage (aSAH) intravenous. Blood samples were taken at different time points during and following infusion with 0.2-0.4mg/kg/h clazosentan, which lasted for up to 14 days. The results show that the pharmacokinetic properties of clazosentan in patients with aSAH are similar to those in healthy subjects. With increasing body weight, higher plasma concentrations were reached, suggesting that clazosentan in future clinical studies can be dosed on a mg/h rather than a mg/kg/h basis.

Original languageEnglish
Title of host publicationCerebral Vasospasm
Subtitle of host publicationNew Strategies in Research and Treatment
PublisherSpringer-Verlag Wien
Pages125-126
Number of pages2
Edition104
ISBN (Print)9783211757178
DOIs
StatePublished - 2008

Publication series

NameActa Neurochirurgica, Supplementum
Number104
ISSN (Print)0065-1419

Keywords

  • Clazosentan
  • body weight
  • endothelin-1
  • patients
  • pharmacokinetics
  • subarachnoid haemorrhage

Fingerprint

Dive into the research topics of 'A pharmacokinetic study of clazosentan in patients with aneurysmal subarachnoid haemorrhage'. Together they form a unique fingerprint.

Cite this